- FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF
-
The present disclosure relates to Fused Morpholinopyrimidines, pharmaceutical compositions comprising an effective amount of a Fused Morpholinopyrimidine and methods for using a Fused Morpholinopyrimidine in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of a Fused Morpholinopyrimidine.
- -
-
-
- FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF
-
The present invention relates to Fused Morpholinopyrimidines, pharmaceutical compositions comprising an effective amount of a Fused Morpholinopyrimidine and methods for using a Fused Morpholinopyrimidine in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of a Fused Morpholinopyrimidine.
- -
-
-
- FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF
-
The present disclosure relates to Fused Morpholinopyrimidines, pharmaceutical compositions comprising an effective amount of a Fused Morpholinopyrimidine and methods for using a Fused Morpholinopyrimidine in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of a Fused Morpholinopyrimidine.
- -
-
-
- Tetrahydroquinoline Derivatives And Their Pharmaceutical Use
-
Tetrahydroquinoline compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and their use in therapy.
- -
-
Page/Page column 44
(2012/08/28)
-
- THETRAHYDROQUINOLINES DERIVATIVES AS BROMODOMAIN INHIBITORS
-
Tetrahydroquinoline compounds of formula (I) or a salt thereof, pharmaceutical compositions containing such compounds and their use in therapy, in particular in the treatment of diseases or conditions for which a bromodomain inhibitor is indicated.
- -
-
-
- TETRAHYDROQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE
-
Tetrahydroquinoline compounds of Formula (I) and salts thereof, pharmaceutical compositions containing such compounds and their use in therapy.
- -
-
Page/Page column 98
(2011/06/11)
-
- SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF
-
The present invention relates to small molecule modulators of mTORCl and mT0RC2, syntheses thereof, and intermediates thereto. Such small molecule modulators are useful in the treatment of proliferative diseases (e.g., benign neoplasms, cancers, inflammatory diseases, autoimmune diseases, diabetic retinopathy) and metabolic diseases. Novel small molecules are provided that inhibit one or more of mTORCl, mT0RC2, and PI3K-related proteins. Novel methods of providing soluble mTORCl and mT0RC2 complexes are discussed, as well as methods of using the soluble complexes in a high- throughput manner to screen for inhibitory compounds.
- -
-
Page/Page column 93-94
(2010/04/30)
-
- 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW MAO INHIBITORS AND IMIDAZOLINE RECEPTOR LIGANDS
-
The present invention is directed to 6-(1H-imidazo-1-yl)-2-aryl and 2-heteroaryl quinazoline and quinolines derivatives, compounds of formula (I), their pharmaceutical acceptable salts and solvates and corresponding pharmaceutical compositions, that acts
- -
-
-
- MODULATORS OF AMYLOID BETA
-
The invention relates to compounds of formula wherein hetaryl I, hetaryl II, and R1 are as described herein. Compounds of formula I are modulators for amyloid beta and thus, they may be useful for the treatment or prevention of a disease associated with the deposition of β-amyloid in the brain, in particular Alzheimer's disease.
- -
-
Page/Page column 24
(2011/07/06)
-
- CARBON-NITROGEN BOND FORMING PROCESS
-
The present invention relates to a process to create a carbon-nitrogen bond by the reaction of an aromatic compound carrying at least one electro attractive group with one nitrogenous heterocyclic type nucleophile compound. The invention aims, in particular, at a link reaction between an aromatic compound carrying at least one electro attractive group and an imidazole heterocycle type. The invention process, consisting of the reaction of an aromatic compound carrying one leaving group and at least one electro attractive group and a nitrogenous heterocyclic type nucleophile compound comprising a N-H pattern likely to substitute the leaving group, thereby creating a carbon-nitrogen bond in the presence of a copper catalyst, of a base in an organic solvent, is characterized by the fact that the said nitrogenous heterocycle reacts with an aromatic type electrophile compound carrying one leaving group (Y) chosen from bromine, chlorine or sulfonic ester and at least one electro attractive group (Z1), in the presence of a copper catalyst, of a mineral or organic base, of an extracting agent selected from aliphatic diamines, aliphatic amino alcohols and diols in a polar aprotic organic solvent with a dielectric constant less than about 20 and a basicity such that its "donor number" is less than about 25.
- -
-
Page/Page column 15
(2008/06/13)
-
- BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES
-
The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non receptor kinases.
- -
-
Page/Page column 188
(2008/06/13)
-